GIST: Molecular Profiling Suggests 2nd Therapy

In an analysis of ctDNA from patients with advanced gastrointestinal stromal tumors, researchers found that, following imatinib therapy, patients with KIT exon 11 plus 17 and/or 18 alterations had superior progression-free survival (PFS) and overall survival (OS) when they received ripretinib as a second-line treatment compared with sunitinib; patients with KIT exon 11 plus 13 and/or 14 alterations had superior PFS and OS with sunitinib compared with ripretinib. The findings highlight the clinical value of molecular testing.